[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334363-105":59,"doc-detail-334363-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dependence-of-npps-creates-a-targetable-vulnerability-in-ras-mutant-cancers","Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers","","The study examines how nucleotide pyrophosphatase (NPPS) supports the growth and survival of cancers driven by diverse RAS mutations. By profiling NPPS expression across RAS-mutant cell lines and combining transcriptomics with metabolomics, the work links NPPS dependence to RAS-mutant–specific hyperglycolysis. Mechanistic assays show NPPS promotes glycolysis by enhancing NPPS interaction with hexokinase 1 (HK1), beyond canonical nucleotide-metabolizing activity. Pharmacologic NPPS inhibition and HK1 inhibition, supported by genetic interference, suppress RAS-mutant cancers in vitro and in vivo, revealing a druggable vulnerability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dependence-of-npps-creates-a-targetable-vulnerability-in-ras-mutant-cancers/334363/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dependence-of-npps-creates-a-targetable-vulnerability-in-ras-mutant-cancers/334363.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is targeting RAS mutants still challenging?","Question",{"text":112,"@type":113},"Direct RAS inhibition has been largely unsuccessful for decades. KRASG12C-specific inhibitors do not apply to tumors driven by other RAS variants and face variable responses and rapid resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the study show about NPPS in RAS-mutant cancers?",{"text":117,"@type":113},"Cancer cells with diverse RAS mutations depend on NPPS for growth and survival. This NPPS dependence creates a vulnerability that can be exploited by NPPS inhibition.",{"name":119,"@type":110,"acceptedAnswer":120},"How does NPPS promote glycolysis in RAS-mutant cells?",{"text":121,"@type":113},"NPPS interacts with hexokinase 1 (HK1) and enhances glycolysis, supporting cancer growth and survival. This occurs independently of NPPS’s canonical nucleotide-metabolizing activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334363,1790191127,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","[www.nature.com/aps](www.nature.com/aps)  \nDependence of NPPS creates a targetable vulnerability in RAS-mutant cancers  \nRui-xue Xia1,2, Pei-chen Zou2, Jun-ting Xie2, Ya-bin Tang2, Miao-miao Gong2, Fu Fan1, Ayinazhaer Aihemaiti2, Yu-qing Liu2, Ying Shen2, Bin-bing S. Zhou 1,2 ✉, Liang Zhu2 ✉ and Hui-min Lei2 ✉  \n\n| | RAS is the most frequently mutated oncoprotein for cancer driving. Understanding of RAS biology and discovery of druggable lynchpins in RAS pathway is a prerequisite for targeted therapy of RAS-mutant cancers. The recent identiﬁcation of KRASG12C inhibitor breaks the “undruggable” curse on RAS and has changed the therapy paradigm of KRAS-mutant cancers. However, KRAS mutations, let alone KRASG12C mutation, account for only part of RAS-mutated cancers. Targeted therapies for cancers harboring other RAS mutations remain the urgent need. In this study we explored the pivotal regulatory molecules that allow for broad inhibition of RAS mutants. By comparing the expression levels of nucleotide pyrophosphatase (NPPS) in a panel of cell lines and the functional consequence of increased NPPS expression in RAS-mutant cells, we demonstrated that cancer cells with various kinds of RAS mutations depended on NPPS for growth and survival, and that this dependence conferred a vulnerability of RAS-mutant cancer to treatment of NPPS inhibition. RAS-mutant cells, compared with RAS-wildtype cells, bored and required an upregulation of NPPS. Transcriptomics and metabolomics analyses revealed a NPPS-dependent hyperglycolysis in RAS-mutant cells. We demonstrated that NPPS promoted glucose-derived glycolytic intermediates in RAS-mutant cells by enhancing its interaction with hexokinase 1 (HK1), the enzyme catalyzing the ﬁrst committed step of glycolysis. Pharmacological inhibition of NPPS-HK1 axis using NPPS inhibitor Enpp-1-IN-1 or HK1 inhibitor 2-deoxyglucose (2-DG), or genetic interfere with NPPS suppressed RAS-mutant cancersin vitro and in vivo. In conclusion, this study reveals an unrecognized mechanism and druggable lynchpin for modulation of panmutant-RAS pathway, proposing a new potential therapeutic approach for treating RAS-mutant cancers. |  |  |  |  |  | |\n| --- | --- | --- | --- | --- | --- | --- | --- |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n| |  |  |  |  |  |  | |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  | RAS-mutant cancers; NPPS; HK1; glycolysis |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n|  | Acta Pharmacologica Sinica (2025) 46:728–739; [https://doi.org/10.1038/s41401-024-01409-2](https://doi.org/10.1038/s41401-024-01409-2) |  |  |  |  |  |  |\n|  |  |  |  |  |  |  |  |\n\nKeywords:  \nINTRODUCTION  \nThe RAS family of proto-oncogenes, including KRAS, NRAS and HRAS, are prevalently mutated in human cancers, which leads to the initiation and progression of tumors [1–4] . Among these, KRAS variants are the most common RAS mutations, with codon 12 being the predominant mutated spot [2, 4] . Despite decades of effort, the quest to directly inhibit RAS has been mostly unsuccessful until recent years. Currently, a number of KRASG12Cspeciﬁc covalent inhibitors, including sotorasib and adagrasib, have received regulatory approval [5–9] . Nevertheless, these inhibitors encounter severe challenges, such as variable responsesand the rapid emergence of drug resistance [10, 11], highlighting the need to develop more effective treatments. Furthermore, KRASG12C inhibitors are not applicable to tumors driven by otheroncogenic RAS variants. Therefore, efforts to discover therapeutics that allow for broad inhibition of RAS mutants are ongoing. Hence, pinpointing the pivotal regulatory molecules of pan-RAS m","cbCaikNqRs6DoCJG","https://ap.wps.com/l/cbCaikNqRs6DoCJG","pdf",4798288,12,"English","# Introduction\n## RAS-driven oncogenesis and limits of direct inhibition\n## Metabolic reprogramming as a targeting strategy\n## NPPS dependence as a vulnerability across RAS mutations","[{\"question\":\"Why is targeting RAS mutants still challenging?\",\"answer\":\"Direct RAS inhibition has been largely unsuccessful for decades. KRASG12C-specific inhibitors do not apply to tumors driven by other RAS variants and face variable responses and rapid resistance.\"},{\"question\":\"What does the study show about NPPS in RAS-mutant cancers?\",\"answer\":\"Cancer cells with diverse RAS mutations depend on NPPS for growth and survival. This NPPS dependence creates a vulnerability that can be exploited by NPPS inhibition.\"},{\"question\":\"How does NPPS promote glycolysis in RAS-mutant cells?\",\"answer\":\"NPPS interacts with hexokinase 1 (HK1) and enhances glycolysis, supporting cancer growth and survival. This occurs independently of NPPS’s canonical nucleotide-metabolizing activity.\"}]","Dependence of NPPS creates a targetable vulnerability in RAS-mutant cancers | PDF",1790006388]